Assessing Moral Cognitive Skills in Adults With Autism Spectrum Disorders

NCT ID: NCT05551260

Last Updated: 2024-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-02

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the international literature, it is currently accepted that, relative to neurotypicals, people with Autism Spectrum Disorder (ASD) present patterns of moral judgments marked by a minimization of intentionality and a strong condemnation of agents responsible for accidents. However, until now, all studies are based on declarative paradigms, and no one has proposed to examine the relationship of people with ASD to moral transgressions (i.e. to a bad action done deliberately or to a good deed deliberately omitted) in an implicit paradigm, that is, when the answer is made on the assignment of an expressive face to these moral offenses. Furthermore, no study has investigated whether diminished sensitivity to intention and intransigence of incidental judgment occur in both automatic (implicit) and deliberative (explicit) settings.

Investigators planned to study how people with ASD without intellectual disability process emotions expressed by others in response to different forms of moral offense and to examine whether patterns potentially contrast in degree and/or kind with those of neurotypicals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the CoMorA project, participants will participate to two independent tasks: an explicit one of deciding whether or not an emotion expressed on the face of a third person would be an appropriate emotional reaction to the offense, and an implicit one in which the subjects will have to determine the fastest sex to which the face expressing such or such an emotion belongs. This procedure initiates an implicit processing of the facial expression.

The theoretical hypotheses of the CoMorA project are the following:

* In the explicit response condition, people with ASD will show different emotional assignment patterns than controls do, depending on the nature of the offense (accidental transgression, attempted harm, and intentional harm).
* In the implicit response condition, people with ASD will exhibit emotion processing patterns identical to those of controls.
* The differences in responses of controls and people with ASD in the explicit condition will be underpinned by executive functions and social cognitive performances.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

This study uses standard neuropsychological tests and a computerized experimental task, submitted to two parallel groups: participants with ASD and control participants matched in age, gender and level of education (1:1 ratio). Participants in both groups completed the neuropsychological tests and the experimental task successively (fixed order for all participants). Within the experimental task, the experimental conditions appear randomly.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

People with ASD

30 people with ASD without IDD

Group Type EXPERIMENTAL

Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition

Intervention Type OTHER

Day 0: sending of the information notice

Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)

Between day 1 and day 21 : second part of the Day 1 tests

Neurotypicals

30 neurotypicals

Group Type ACTIVE_COMPARATOR

Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition

Intervention Type OTHER

Day 0: sending of the information notice

Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)

Between day 1 and day 21 : second part of the Day 1 tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition

Day 0: sending of the information notice

Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)

Between day 1 and day 21 : second part of the Day 1 tests

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

ASD group:

* Diagnosis of ASD according to DSM-5 criteria
* Age between 18 and 40 years old
* Francophone
* Affiliated to social security
* Having given their consent to participate in the study
* Patient under guardianship and curatorship

Neurotypical group:

* Age between 18 and 40 years old
* Francophone
* Affiliated to a social security scheme
* Having given their consent to participate in the study

Exclusion Criteria

ASD group:

* Diagnosis of intellectual development disorder established according to DSM-5 criteria
* Language, sensory or motor impairments hindering participation in the study

Control group:

* Neurodevelopmental pathology (declarative)
* Neurological pathology
* Language, sensory or motor impairments hindering participation in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hôpital le Vinatier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elodie PEYROUX

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier le Vinatier

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

centre de réhabilitation - Hôpital le Vinatier

Lyon, Rhône, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elodie PEYROUX, PhD

Role: CONTACT

04.37.91.51.63 ext. +33

Lydie SARTELET

Role: CONTACT

04.37.91.55.31 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Franck Nicolas, PUPH

Role: primary

+33 (0)4 26 23 76 11

Gaudelus Baptiste

Role: backup

+33 (0)4 26 23 76 11

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A01040-43

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.